Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02498392 · ClinicalTrials.gov registry record · Phase 2

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

A Phase 2 study of Anxiety and Depressive Disorder, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 2
Development phase
161
Enrollment target
20
Study locations

NCT02498392 is a Phase 2 study of Anxiety and Depressive Disorder that has completed, run by Janssen Research & Development. The registered enrollment target is 161 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02498392, a Phase 2 study of Anxiety and Depressive Disorder, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 2
Development phase
161 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonergic/noradrenergic reuptake inhibitor (SNRI).

Conditions Studied

Anxiety Depressive Disorder

Interventions

  • OTHER Placebo
  • DRUG JNJ-42165279

Study Locations (20)

Other

  • - Chisinau
  • - Orenburg
  • - Saint Petersburg
  • - Saratov
  • - Tomsk
  • - Yekaterinburg
  • - Alicante
  • - Barcelona
  • - Bilbao
  • - Sant Boi de Llobregat
  • - Zamora
  • - Hlevakha

California

  • - Costa Mesa
  • - Oceanside

Florida

  • - Miami

Massachusetts

  • - Natick

New York

  • - Cedarhurst

North Carolina

  • - Raleigh

Pennsylvania

  • - Allentown

Utah

  • - Salt Lake City

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2015-10-07
Est. Completion 2019-02-04
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02498392

The ClinicalTrials.gov registry entry for NCT02498392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (63% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02498392 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02498392 about?

NCT02498392 is a clinical study titled "An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress". The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonergic/noradrenergi...

What is the current status of trial NCT02498392?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2015-10-07. Estimated completion is 2019-02-04.

What conditions does trial NCT02498392 study?

This clinical trial studies the following conditions: Anxiety, Depressive Disorder.

What interventions are being tested in trial NCT02498392?

The interventions under investigation include: Placebo (OTHER), JNJ-42165279 (DRUG).

Who is sponsoring clinical trial NCT02498392?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02498392 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anxiety

All registered trials for this condition

Depressive Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.